Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Wallace Rivers who wrote (14057)	2/2/1998 9:17:00 AM
From: tonyt	Read Replies (1) \| Respond to of 32384

> I would think the more relevant question would be what this means > for the smaller fish, in this case specifically LGND. That would be the relevent question, but as you've noticed, it has been avoided. These mergers will do nothing (barring a buyout of LGND) for Ligand as these big-pharma's now have a lot of work ahead of them to get the merger to work. I doubt that they care about LGND (and leptin deals) right now. Good Luck, --Tony

To: Wallace Rivers who wrote (14057)	2/2/1998 9:35:00 AM
From: Henry Niman	Respond to of 32384

Wallace, I addressed the LGND impact briefly, in terms of it's partners and overlapping or non-overlapping programs. LGND of course has alliances with the three major players (AHP, GLX, SBH). It looks like the GLX/SBH is now the first that will happen and LGND's programs don't overlap (GLX focuses on athrosclerosis using IR techology that focuses on LDL modulators and PPARs). GLX is expected to file an IND on one of the LDL modulators selected by LGND. LGND's SBH allliance is on hematopoetic growth factors (small molecules that would mimic the effects of injected poplypeptide hormones such as the blockbuster, Epogen). Thus there is no overlap amoung the alliances partners. Of course right now there are many wildcards. AHP is left at the alter, but most expect a new deal soon. Similarly, most of the major pharmas will be affected, so the landscape should change. However, since LGND has alliances with over 20% of the pharmaceutical industry, it's clear that the drug sector loves LGND, and I expect the interest to increase.